Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308732 | 0.90 | MEN1 (0.36) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL27461956 | 0.90 | FOLH1 (0.45) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL2778138 | 0.88 | BID (0.38) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL28457170 | 0.87 | BID (0.40) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL28453652 | 0.87 | BID (0.40) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL8652707 | 0.84 | HMGB1 (0.54) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL27784726 | 0.84 | SIRT1 (0.43) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL1337735 | 0.83 | ALDH1A1 (0.47) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL1063004 | 0.82 | BID (0.41) | KDM4EALDH1A1MAPTHPGDTSHR | |
| SCHEMBL28204613 | 0.81 | PARP1 (0.39) | KDM4EALDH1A1MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687070-B2 | Reagents for intracellular delivery of macromolecules | Life Technologies Corporation (US) | 2010-03-30 | — | — | US | disclosed |
| US-6989434-B1 | Reagents for intracellular delivery of macromolecules | INVITROGEN CORPORATION (US) | 2006-01-24 | — | — | US | disclosed |
| US-20050260757-A1 | Novel reagents for intracellular delivery of macromolecules | INVITROGEN COROPORATION (US) | 2005-11-24 | — | — | US | disclosed |
| CN-1143675-C | Heteroarylpiperidines, pyrrolidines and piprazines and their use as antipsychotics and analgetics | ���µ�˹ҩ�﹫˾ | 2004-03-31 | — | — | CN | disclosed |
| US-6075012-A | TRANSFECTION | LIFE TECHNOLOGIES, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| CN-1136275-A | Arylheterocyclylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgesics | HOECHST ROUSSEL PHARMA (US) | 1996-11-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050260757-A1 | Novel reagents for intracellular delivery of macromolecules | NPC1L1, CETP, LIPA | KDM4E 3854/4885ALDH1A1 4440/4885MAPT 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.